Diagnostic Effectiveness of Transforming Growth Factor Beta 1 in Assessing the Risk of Developing Graft Dysfunction in Liver Recipient Children by R. M. Kurabekova, O. M. Tsiroulnikova, I. E. Pashkova, A. G. Olefirenko, O. E. Gichkun, L. V. Makarova, R. A. Monakhov, P. O. Shevchenko

“…Transforming growth factor beta 1 (TGF-β1) is a pleiotropic cytokine with a profibrogenic and immunosuppressive effect that can have a definite effect on the liver transplant functioning.Aim. …”
Get full text

29 m6A-RNA Methylation (Epitranscriptomic) Regulators Are Regulated in 41 Diseases including Atherosclerosis and Tumors Potentially via ROS Regulation – 102 Transcriptomic Dataset... by Ming Liu, Keman Xu, Fatma Saaoud, Ying Shao, Ruijing Zhang, Yifan Lu, Yu Sun, Charles Drummer, Li Li, Sheng Wu, Satya P. Kunapuli, Gerard J. Criner, Jianxin Sun, Huimin Shan, Xiaohua Jiang, Hong Wang, Xiaofeng Yang

“…We performed a database mining on 102 transcriptomic datasets for the expressions of 29 m6A-RNA methylation (epitranscriptomic) regulators (m6A-RMRs) in 41 diseases and cancers and made significant findings: (1) a few m6A-RMRs were upregulated; and most m6A-RMRs were downregulated in sepsis, acute respiratory distress syndrome, shock, and trauma; (2) half of 29 m6A-RMRs were downregulated in atherosclerosis; (3) inflammatory bowel disease and rheumatoid arthritis modulated m6A-RMRs more than lupus and psoriasis; (4) some organ failures shared eight upregulated m6A-RMRs; end-stage renal failure (ESRF) downregulated 85% of m6A-RMRs; (5) Middle-East respiratory syndrome coronavirus infections modulated m6A-RMRs the most among viral infections; (6) proinflammatory oxPAPC modulated m6A-RMRs more than DAMP stimulation including LPS and oxLDL; (7) upregulated m6A-RMRs were more than downregulated m6A-RMRs in cancer types; five types of cancers upregulated ≥10 m6A-RMRs; (8) proinflammatory M1 macrophages upregulated seven m6A-RMRs; (9) 86% of m6A-RMRs were differentially expressed in the six clusters of CD4+Foxp3+ immunosuppressive Treg, and 8 out of 12 Treg signatures regulated m6A-RMRs; (10) immune checkpoint receptors TIM3, TIGIT, PD-L2, and CTLA4 modulated m6A-RMRs, and inhibition of CD40 upregulated m6A-RMRs; (11) cytokines and interferons modulated m6A-RMRs; (12) NF-κB and JAK/STAT pathways upregulated more than downregulated m6A-RMRs whereas TP53, PTEN, and APC did the opposite; (13) methionine-homocysteine-methyl cycle enzyme Mthfd1 downregulated more than upregulated m6A-RMRs; (14) m6A writer RBM15 and one m6A eraser FTO, H3K4 methyltransferase MLL1, and DNA methyltransferase, DNMT1, regulated m6A-RMRs; and (15) 40 out of 165 ROS regulators were modulated by m6A eraser FTO and two m6A writers METTL3 and WTAP. …”
Get full text

Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report by Yuki Miyata, Ryo Yamaguchi, Takehito Yamamoto, Toshiyuki Kishida, Kazuhiko Ikeuchi, Hiroaki Harada, Takeya Tsutsumi, Keishi Fujio, Tappei Takada

“…Tacrolimus (TAC) is a widely used immunosuppressive agent whose blood level can increase significantly due to the inhibition of cytochrome P450 3A (CYP3A) and P-glycoprotein by nirmatrelvir/ritonavir. …”
Get full text

The Effects of Mesenchymal Stem Cells on Antimelanoma Immunity Depend on the Timing of Their Administration by Dragana Miloradovic, Dragica Miloradovic, Bojana Simovic Markovic, Aleksandar Acovic, Carl Randall Harrell, Valentin Djonov, Nebojsa Arsenijevic, Vladislav Volarevic

“…Significantly higher plasma levels of antitumorigenic cytokines (TNF-α and IFN-γ), remarkably lower plasma levels of immunosuppressive cytokines (TGF-β and IL-10), and a significantly higher number of tumor-infiltrating, IFN-γ-producing, FasL- and granzyme B-expressing NK cells, IL-17-producing CD4+Th17 cells, IFN-γ- and TNF-α-producing CD4+Th1 cells, and CD8+cytotoxic T lymphocytes (CTLs) were observed in B16F10+MSC1d-treated mice. …”
Get full text

Arginase-1-specific T cells target and modulate tumor-associated macrophages by Mads Hald Andersen, Inés Lecoq, Ayako Wakatsuki Pedersen, Evelina Martinenaite, Shamaila Munir Ahmad, Maria Perez-Penco, Lucia Lara de la Torre, Marion Chapellier, Lars Rønn Olsen, Mia Aaboe-Jørgensen, Hannah Jorinde Glöckner, Anne Mette Askehøj Rømer

“…The effect of Arg1-derived peptide IMV on TAMs in vivo was assessed by multiplex gene analysis of F4/80+cells.Results We show that Arg1-based IMV-mediated tumor control was linked to a decrease in multiple immunosuppressive pathways in the TAM population of the treated animals. …”
Get full text

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report by Hongyan Liu, Colleen Callahan, Shannon L Maude, Kevin Owen McNerney, Rebecca M Richards, Paibel Aguayo-Hiraldo, Friso G Calkoen, Julie-An Talano, Amy Moskop, Adriana Balduzzi, Jennifer Krajewski, Hema Dave, Anant Vatsayan, Yimei Li, Kara Lynn Davis

“…Patients undergoing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell malignancies are uniquely immunosuppressed due to CAR T-mediated B-cell aplasia (BCA). …”
Get full text

4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models by Ignacio Melero, Alvaro Teijeira, Christian Klein, Maria E Rodriguez-Ruiz, Christina Claus, Pablo Umana, Tamara Tanos, Carlos E De Andrea, Carlos Luri-Rey, Paloma Sanchez-Mateos, Leticia Fernández-Rubio, María Collantes, Irantzu Serrano-Mendioroz, Celia Barrio-Alonso, Antonio Rullan, Jon Ander Simon, Eneko Garate-Soraluze, Claudia del Pilar Herrero

“…Background Ionizing radiation (IR) is a double-edged sword for immunotherapy as it may have both immunosuppressive and immunostimulatory effects. The biological effects of IR on the tumor microenvironment (TME) are a key factor for this balance. …”
Get full text

Exploration of rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environment by Xiaolong Wang, Xueying Cao, Jie Wu, Shuang Liang, Jian Yang, Hong Wang

“…We collected clinical data from these patients and categorized them into three groups on the basis of their RTX treatment background: the combined glucocorticoids (GCs) and/or immunosuppressants (IMS) and RTX monotherapy treatment groups, the initial and non-initial treatment groups, and the standard RTX and non-standard RTX treatment groups. …”
Get full text

Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins by Maria Angelica Freitas-Cortez, Fatemeh Masrorpour, Hong Jiang, Iqbal Mahmud, Yue Lu, Ailing Huang, Lisa K. Duong, Qi Wang, Tiffany A. Voss, Claudia S. Kettlun Leyton, Bo Wei, Wai-Kin Chan, Kevin Lin, Jie Zhang, Efrosini Tsouko, Shonik Ganjoo, Hampartsoum B. Barsoumian, Thomas S. Riad, Yun Hu, Carola Leuschner, Nahum Puebla-Osorio, Jing Wang, Jian Hu, Michael A. Davies, Vinay K. Puduvalli, Cyrielle Billon, Thomas P. Burris, Philip L. Lorenzi, Boyi Gan, James W. Welsh

“…Abstract Background Cancer creates an immunosuppressive environment that hampers immune responses, allowing tumors to grow and resist therapy. …”
Get full text

Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade by Shaoyong Peng, Minshan Wu, Qian Yan, Gaopo Xu, Yumo Xie, Guannan Tang, Jinxin Lin, Zixu Yuan, Xiaoxia Liang, Ze Yuan, Jingrong Weng, Liangliang Bai, Xiaolin Wang, Huichuan Yu, Meijin Huang, Yanxin Luo, Xiaoxia Liu

“…Abstract Background Immunotherapy is beneficial for some colorectal cancer (CRC) patients, but immunosuppressive networks limit its effectiveness. Cancer‐associatedfibroblasts (CAFs) are significant in immune escape and resistance toimmunotherapy, emphasizing the urgent need for new treatment strategies. …”
Get full text

Dynamic Challenges of Active Tuberculosis: Prevalence and Risk Factors of Co-Infection in Clinical and Microbiological Characteristics at King Abdulaziz University Hospital, Jeddah... by Mokhtar JA, Attallah DM, Jiman-Fatani AA, Al-Rabia MW, Alqarni MA, Saleh BH, Amboon MM, Altorki TA, Alkuwaity KK, Abujamel T, Kaki R, Albarakati TN, Daghistani H, Ismail MA, Alharbi O, Abu ITM, Alfadil A, Ibrahem K, Mufrrih M, Sait AM

“…Immunocompromising conditions, including comorbidities, malignancies, and the use of immunosuppressive agents, are major risk factors for active TB (ATB).Objective: To analyze clinical factors and estimate mortality in TB and drug-resistant cases.Methods: This retrospective study analyzed medical records of 12,494 patients at KAUH (2019– 2021), identifying 131 confirmed TB cases with comprehensive data on demographics, clinical features, comorbidities, diagnostics, and outcomes. …”
Get full text

Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR by Pui Yeng Lam, Natacha Omer, Josh K. M. Wong, Cui Tu, Louisa Alim, Gustavo R. Rossi, Maria Victorova, Hannah Tompkins, Cheng‐Yu Lin, Ahmed M. Mehdi, Amos Choo, Melissa R. Elliott, Elaina Coleborn, Jane Sun, Timothy Mercer, Orazio Vittorio, Lachlan J. Dobson, Alexander D. McLellan, Andrew Brooks, Zewen Kelvin Tuong, Seth W. Cheetham, Wayne Nicholls, Fernando Souza‐Fonseca‐Guimaraes

“…However, CAR‐T cells have faced significant challenges and limited success in treating solid tumours due to issues such as poor tumour infiltration, immunosuppressive tumour microenvironments and off‐target effects. …”
Get full text